Overall, G-CSF therapy was not associated with a reduced risk of death (30-day survival, OR = 1.55, 95% CI: 1.00, 2.38, <i>P</i> = 0.05; 60-day survival, OR = 1.50, 95% CI: 0.95, 2.36, <i>P</i> = 0.08; 90-day survival, OR = 1.61, 95% CI: 0.99, 2.62, <i>P</i> = 0.05) or complication including occurrence of infections infection (OR = 0.66, 95% CI: 0.41, 1.05, <i>P</i> = 0.08), bleeding (OR = 1.50, 95% CI: 0.58, 3.89, <i>P</i> = 0.41), and hepatorenal syndrome (OR = 0.56, 95% CI: 0.25, 1.24, <i>P</i> = 0.15). The gene discussed is CSF3; the disease is liver disorder.